John S Thompson

Summary

Publications

  1. ncbi request reprint Use of a T cell-specific monoclonal antibody, T10B9, in a novel allogeneic stem cell transplantation protocol for hematologic malignancy high-risk patients
    John S Thompson
    Division of Allergy and Immunology, Markey Cancer Center, University of Kentucky, Lexington, KY 40502, USA
    Biol Blood Marrow Transplant 10:858-66. 2004
  2. ncbi request reprint Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial
    John E Wagner
    University of Minnesota Blood and Marrow Transplantation Program, Minneapolis, MN 55455, USA
    Lancet 366:733-41. 2005

Collaborators

Detail Information

Publications2

  1. ncbi request reprint Use of a T cell-specific monoclonal antibody, T10B9, in a novel allogeneic stem cell transplantation protocol for hematologic malignancy high-risk patients
    John S Thompson
    Division of Allergy and Immunology, Markey Cancer Center, University of Kentucky, Lexington, KY 40502, USA
    Biol Blood Marrow Transplant 10:858-66. 2004
    ..In conclusion, single-agent chemotherapy conditioning with T10B9 produced durable engraftment and long-term survival in some patients who would not have qualified for a traditional allo-SCT...
  2. ncbi request reprint Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial
    John E Wagner
    University of Minnesota Blood and Marrow Transplantation Program, Minneapolis, MN 55455, USA
    Lancet 366:733-41. 2005
    ..A multi-centre, randomised trial was undertaken to determine the effects of ex-vivo T-cell depletion versus methotrexate and cyclosporine immunosuppression on 3-year disease-free survival...